Company Crossject Deutsche Boerse AG
Equities
74C
FR0011716265
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.826 EUR | +2.70% | +16.16% | -59.78% |
07-10 | Markets Powered by Alternating Current | |
07-10 | Crossject Gets EUR7 Million Public Funding for New Epinephrine Product | MT |
Business Summary
Number of employees: 105
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Needle-free Injection System
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -84.80% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -84.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 07/08/01 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 31/12/15 |
General Counsel | - | 31/12/12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 06/06/23 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
Yannick Plétan
BRD | Director/Board Member | - | - |
Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,086,652 | 27,118,311 ( 73.12 %) | 135,869 ( 0.3664 %) | 73.12 % |
Stock B | 0 | 1,655,925 | 0 | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CROSSJECT 0.26% | 107,541 | 0.26% | 187,408 $ |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.50% | 261M |
- Stock Market
- Equities
- ALCJ Stock
- 74C Stock
- Company Crossject